Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors
Open Access
- 17 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 100 (18), 1282-1289
- https://doi.org/10.1093/jnci/djn275
Abstract
A National Cancer Institute summit meeting on gastroenteropancreatic neuroendocrine and carcinoid tumors was held in September 2007 to present the currently accepted standards of care for patients with these tumors and to identify areas requiring investigation and development. These tumors are clinically and pathologically heterogeneous, present commonly with obscure symptoms that lead to delays in diagnosis of years, and have an incidence in the United States of 2.5 to 5 cases per 100 000. The 5-year survival rates range between 15% and 95%, depending on the site and extent of disease. This report delineates the main conclusions of the meeting, including the best practice diagnosis and treatment strategies for gastropancreatic neuroendocrine tumors, and the identification of clinical and scientific areas that are most in need of attention. The most pressing needs were public and physician education, identification of molecular markers for early diagnosis and therapeutic monitoring, improved imaging modalities and molecular prognostication, development of a standardized pathological classification system, and creation of regional centers of expertise with tumor and laboratory data banks. In addition, adequately validated neuroendocrine tumor models and cell lines should be established to investigate the molecular mechanisms involved in the control of their growth and secretion, and to facilitate the development of specific therapies that should be examined in well-designed multicenter studies of defined patient groups.Keywords
This publication has 41 references indexed in Scilit:
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Identification of stem cells in small intestine and colon by marker gene Lgr5Nature, 2007
- Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based StudyGastroenterology, 2007
- Drugs and Valvular Heart DiseaseNew England Journal of Medicine, 2007
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBritish Journal of Cancer, 2006
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Prognosis of Carcinoid Heart DiseaseCirculation, 2005
- Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)Best Practice & Research Clinical Gastroenterology, 2005
- Endocrine tumours of the pancreasBest Practice & Research Clinical Gastroenterology, 2005
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003